Allworth Financial
CADL icon

Allworth Financial’s Candel Therapeutics CADL Stock Holding History

Allworth Financial’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2K Hold
194
– – ﹤0.01% 4647
2026
Q2 		$2K Buy
194
+62
+47% +$468 ﹤0.01% 4522
2026
Q1 		$647 Buy
+132
New +$718 ﹤0.01% 4679
2025
Q2 		– Sell
-45
Closed -$225 – 4599
2025
Q1 		$225 Buy
+45
New +$368 ﹤0.01% 3847

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Kennedy Capital Management
Kennedy Capital Management St Louis, Missouri $5.31B AUM 40.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Sands Capital Ventures
Sands Capital Ventures Arlington, Virginia $695M AUM 31.12% 1-Year Est. Return

Allworth Financial's CADL Position: Q3 2026 in Review

Allworth Financial held its Candel Therapeutics (CADL) position steady in Q3 2026 at 194 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #4647.

Allworth Financial first reported a position in CADL in Q1 2025 and has held it in 4 quarters since. 106 funds tracked by Wall St. Rank hold CADL as of Q3 2026.

  • Allworth Financial held 194 shares of Candel Therapeutics worth $2K as of Q3 2026.
  • Allworth Financial left its Candel Therapeutics share count unchanged in Q3 2026.
  • Candel Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q3 2026, its #4647 holding.
  • Allworth Financial first reported a position in Candel Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • 106 funds tracked by Wall St. Rank held Candel Therapeutics as of Q3 2026.

Based on Allworth Financial's 13F filing for Q3 2026, filed 6 Nov 2026.